TORONTO, ONTARIO--(Marketwired - April 18, 2013) - Biologix Hair Inc. (OTCBB:BLGX) (OTCQB:BLGX) announces the Company has established a Medical Advisory Board and named Dr. Craig Ziering as its Chairman.
Dr. Ziering received his Doctorate of Osteopathic Medicine from Nova Southeastern University in Miami, Florida and completed his residency at Ohio University's Grandview Medical Center, Dayton, Ohio. After completing a Fellowship in Hair Restoration with Medical Hair Restoration in Orlando, Dr. Ziering became the Associate Medical Director at MHR for a period of ten years before founding his private practice, Ziering Medical, in 2003. Ziering's world headquarters is in Beverly Hills, California and now has surgical centers throughout the United States, Europe, the Middle East and Asia. Dr. Ziering is certified by both the American Board of Hair Restoration Surgery and the American Osteopathic Board of Dermatology and is known in Hollywood as "The Hair Restoration Surgeon to the Stars."
A past president of the American Osteopathic College of Dermatology, Dr. Ziering serves on advisory boards for various companies including Merck, Lexington International and Viviscal, on the scientific advisory board of Histogen (a Regenerative Medicine company) and is on the Surgical Faculty for the Procedural Dermatology Fellowship at the University of California at Irvine, Dermatology Faculty, Western University/Pacific Hospital, Long Beach, California and Michigan State University, Dermatology Faculty. Additionally, Dr. Ziering is a consultant and R&D Center for Restoration Robotics and consultant for Kythera, as well as being the Primary Investigator for hair clinical trials for Histogen.
As a recognized expert in the art and science of hair transplant surgery, Dr. Ziering is a frequent guest on television and radio programs including "The Today Show." In addition to being invited to perform the first hair transplant procedure on the ABC hit "Extreme Makeover," he was chosen to premier his "sneak-peek long hair transplant" procedure on the cutting-edge E! reality show, "Dr. 90210."
In 2003, Dr. Ziering was recognized by his peers at the International Society for Hair Restoration Surgeons for his Whorl Hair Classification System being awarded the prestigious "Most Original New Idea" at that year's scientific assembly.
Ron Holland, Biologix Director and CEO, stated, "As we continue to rapidly develop our international network of clinicians and medical practitioners seeking to become certified Biologix Hair Therapists™ and to secure exclusive territorial treatment rights for the Biologix Hair Therapy System™, we deem it of great value to build a Medical Advisory Board comprised of leading medical professionals who can provide ongoing advice and assistance.
"Dr. Ziering is one of the contracting clinicians who recognized the value opportunity of our patent pending hair formula, Biologix Revive. We welcome Dr. Ziering to the Biologix team and look forward to working together to build a top-notch board of medical advisers."
About Biologix Hair Inc. and Biologix Hair Science Ltd.
Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System™ - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.
Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System™ - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.
BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.
Additionally, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 144 countries have as of now contracted, including Canada and the United States.
Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™, if and when FDA and other major market approvals are forthcoming.
As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.
Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System™ is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.
To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.
This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities as well as the ability for Biologix to obtain adequate financing to meet its business objectives. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.